PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34316328-8	2021	Both H727 and H720 cells were associated with induction of apoptosis, upregulation of the p21 cell cycle inhibitor, and downregulation of the PI3K/Akt/mTOR pathway, suggesting that the PI3K/Akt/mTOR pathway is a primary target of the AZ+SFN combination therapy.	Acetazolamide	234-236	AKT serine/threonine kinase 1	Homo sapiens	190-193	
34316328-0	2021	Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis.	Acetazolamide	95-108	AKT serine/threonine kinase 1	Homo sapiens	174-177	
34316328-9	2021	CONCLUSIONS: Combining SFN+AZ significantly inhibits the PI3K/Akt/mTOR pathway and significantly reducing 5-HT secretion in carcinoid syndrome.	Acetazolamide	27-29	AKT serine/threonine kinase 1	Homo sapiens	62-65	
34316328-8	2021	Both H727 and H720 cells were associated with induction of apoptosis, upregulation of the p21 cell cycle inhibitor, and downregulation of the PI3K/Akt/mTOR pathway, suggesting that the PI3K/Akt/mTOR pathway is a primary target of the AZ+SFN combination therapy.	Acetazolamide	234-236	AKT serine/threonine kinase 1	Homo sapiens	147-150	
24155029-8	2014	Increased expression of PTEN, along with decreased expression of Akt1, also showed that acetazolamide treatment resulted in death inducing autophagy.	Acetazolamide	88-101	AKT serine/threonine kinase 1	Homo sapiens	65-69	
24155029-9	2014	Collectively the results indicate that autophagy is an adequate mechanism mediating the anti-cancer effects of acetazolamide in T-47D cells through engagement of p53/DRAM pathway and attenuation of Akt survival signalling.	Acetazolamide	111-124	AKT serine/threonine kinase 1	Homo sapiens	198-201